RE:Update Alot of info that most of us already know... one thing stuck out to me.. by waiting for more advanced biomarkers. this could turn out to be a combined clincial 1 and 2 ... normally clincial 1 are to measure toxicity of the drug. PMn plans to first check toxicity and based on biogen data.. that toxicity including bleeding in the brain happens very quickly, so PMN wont have to wait long... if you look at the previous report by the CMO, you will see that the plan is to also start dosing in different % and they plan on taking further and including people in various stages of AD. If this shows success and PMN appears to be very confident on what the results will be... this now puts us into the area where FDA can implement their new policy that if a drug is showing success at the very early stages , they can fast track it. All of this is for the sake of the big guy... we dont want to be manaufacturing and distributing the PMN310 .. this is all for the purpose of inticing the AD take over by one the top 10 pharmas. We could be looking at late 2019 early 2020 but beiing able to have actual results of the drugs abillity to deal with AD puts a posiible buyout anytime.
Right now I am watching this develop and when it happens next year or the year after I will be very pleased. For the time being my main focus is on the PD deal. If you look at what similar type of deals brought to the company... I expect the stock to jump to the point that we have not seen since 2008.